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-DRB1 haplotypes on low/intermediate resolution level are con-
sidered, the corresponding values are 85.0% and 97.2%.
These results quantify the decrease in matching probabilities
through more elaborated matching criteria. Signiﬁcant further
recruitment efforts are necessary to maintain high probabilites to
ﬁnd optimal donors as the criteria for optimal donors become more
demanding.
AUTOLOGOUS TRANSPLANTS
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AMD3100 PLUS G-CSF MOBILIZES THE MAJORITY OF NON-HODGKIN’S
LYMPHOMA (NHL), MULTIPLE MYELOMA (MM), AND HODGKIN’S DIS-
EASE (HD) PATIENTS WHO FAILED PRIOR MOBILIZATION WITH
OTHER REGIMENS
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Background: AMD3100, an inhibitor of SDF1 binding to
CXCR4, synergizes with G-CSF to allow mobilization of sufﬁcient
CD34 cells/kg for autologous transplantation in pts unable to
collect adequate CD34 cells with G-CSF alone. A single pt use
(SPU) protocol for AMD3100 was adopted for1 pt entry per site
and termed Compassionate Use Protocol (CUP). The only differ-
ence of standard of care was the addition of AMD3100 to a G-CSF
mobilization on the evening prior to each day of apheresis. Pts who
could not proceed to apheresis due to low peripheral blood counts
or pts who did not collect a minimum of 2  10^6 CD34 cell/kg
were eligible. Methods: Overall, more than 280 patients with
proven poor mobilization including 137 NHL, 73 MM, and 31
HD have been included in CUP. A data audit was performed to
validate data from these pts. Sites were selected based on most
patients entered, 3 of all diseases entered at a site, and sites
conducting an AMD3100 trial. Audit included all pts, regardless of
of the outcome; all information was collected on CRFs. Success of
outcome was collection of 210^6 CD34 cells/kg during the
CUP procedure. CUP apheresis was done on day 5 after G-CSF
(10mg/kg SC QD) and AMD3100 (240mg/kg SC Q10 PM) start-
ing day 4. Results: Charts and CRFs were available for review for
115 pts; 63 (55%) were NHL patients from 29 sites, 35 (30%) were
MM from 23 sites and 17 (15%) were HD from 13 sites. Of these
pts, 58% were male, the median age was 59 yrs (range 21-77), 88%
were Caucasian, and pt weight ranged from 43-128 kg. Prior
treatments included a median of 2 regimens of chemotherapy in
each of the 3 groups. Safety was generally favorable with no
drug-related SAE s and with an AE proﬁle similar to that seen in
research trials. The rates of successful collection of 210^6
CD34 cells/kg per disease state as well as prior mobilization
regimen are summarized in table 1. The median number of mo-
bilizations for the successful patients was 3 days for NHL and HD
and 4 for MM. 88 of the patients underwent transplantation with
any cells; of the 47 NHL patients transplanted, 24 had CUP only
cells and 23 had mixed cells. The median number of days to
engraftment was 11 for PMN and 18 for platelets. Long term
follow up is limited, but there do not appear to be graft failures. At
least 12 of the pts have died. Conclusions: AMD3100 in a poor
mobilizer population is generally safe and well tolerated and is very
effective in mobilizing  210^6 CD34 cells/kg.
Mobilization success rate by disease state: overall and prior
mobilization regimen
Overall Prior Cytokine Prior Chemotherapy
NHL 60% 53% 68%
HD 76% 78% 75%
MM 71% 73% 71%
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Background: No standard approach for the mobilization of
peripheral hematologic stem and progenitor cells (HSPCs) has
been established. High levels of circulating CD34 cells, a
surrogate marker for mobilization efﬁciency, are associated with
less apheresis days. A higher dose of CD34 cell transfused
after high-dose chemotherapy decreases time to hematologic
recovery. Consequently, a better understanding of variables
associated with mobilization kinetics may further optimize stem
cell collection and reduce complications associated with autol-
ogous stem cell transplants. Methods: The Washington Uni-
versity (St. Louis, MO) transplantation database includes clini-
cal parameters from 407 multiple myeloma (MM), 567 non-
Hodgkins Lymphoma (NHL), and 164 Hodgkin s disease (HD)
pts who received an ASCT between 1995 and 2006. A retro-
spective analysis of this large pt population was conducted to
determine factors associated with the mobilization kinetics of
CD34 cells. Results: Table 1 summarizes the mobilization
kinetics as deﬁned by number of days to reach a target of 2 
10^6 CD34 cells/kg. Overall, the median number of aphereses
to reach the target were 1, 2, and 2 in MM, NHL, and HD,
respectively. Daily median CD34 yields in MM pts were 3.8,
1.2, and 0.5  10^6 on day 1-3, respectively. In NHL pts, yields
were 1.4, 0.8, and 0.4  10^6 on day 1-3. In HD pts, yields were
1.8, 0.8, and 0.3  10^6 on day 1-3, respectively. The addition
of chemotherapy increased the % of pts requiring only a single
apheresis to reach the mobilization target. Table 2 summarizes
the mobilization kinetics for each re-mobilization regimen. In
general, a limited number of cells was collected with each
aphereses; 70% of pts failed to mobilize 2  10^6 CD34
cells/kg. In contrast, remobilization with AMD3100 allowed the
collection of sufﬁcient CD34 cells in 67% of pts; median
number of apheresis to reach the target was 3. Conclusions:
Factors associated with mobilization kinetics of CD34 cells
include disease state and mobilization regimen. Re-mobilization
is associated with high failure rates, re-mobilization regimens
including AMD3100 are more successful.
Mobilization kinetics by (1) disease state, and (2) re-mobilization
regimen
Table 1 > 210^6 CD34/kg: Day 1 Day 2 Day 3-5 Failed
MM G-CSF 59.3% 17.9% 16.3% 6.5%
G-CSF/Chemo 88.2% 0% 5.9% 5.9%
NHL G-CSF 29.7% 20.6% 23.2% 26.5%
G-CSF/Chemo 42.9% 22.8% 11.4% 22.9%
HD G-CSF 32.3% 23.9% 17.6% 26.2%
G-CSF/Chemo 33.3% 25.0% 25.0% 16.7%
Table 2 > 210^6 CD34/kg: Day 1 Day 2 Day 3-5 Failed
G-CSF 2.3% 5.7% 6.3% 85.7%
G-CSF/GM 4.8% 7.9% 14.3% 73%
G-CSF/Chemo 4.5% 13.7% 6.8% 75%
AMD3100 12.5% 25.0% 29.5% 33%
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